Image

Global Tamiflu (Oseltamivir Phosphate) Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Tamiflu (Oseltamivir Phosphate) Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Tamiflu (Oseltamivir Phosphate) Drugs Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 542.88 USD Billion
Diagram Market Size (Forecast Year) USD 862.85 USD Billion
Diagram CAGR %

Major Markets Players

  • Pfizer
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V
  • Teva Pharmaceutical Industries Ltd

Global Tamiflu (Oseltamivir Phosphate) Drugs Market, By Drug Class (Neuraminidase Inhibitors, Others), Type (Branded, Generic), Patient Demographic (Adults, Geriatric, Pediatric), Indication (Influenza A, Influenza B, Others), Dosage Form (Capsule, Suspension), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Tamiflu (Oseltamivir Phosphate) Drugs Market

Market Analysis and Size                              

The tamiflu (oseltamivir phosphate) market is changing as healthcare organizations, particularly in the United States, are increasingly shifting to OTC distribution. As the United States is one of North America's fastest-growing economies, it is anticipated to have the second-highest revenue in the tamiflu (oseltamivir phosphate) market by 2027. As a result, corporations in the United States are cashing in on the OTC switch trend. According to prominent market players, even emerging market companies are striving for the OTC switch and strategic transactions to introduce tamiflu (oseltamivir phosphate) advancements.

Data Bridge Market Research analyses that the tamiflu (oseltamivir phosphate) drugs market was valued at USD 542.88 billion in 2021 and is expected to reach USD 862.85 billion by 2029, registering a CAGR of 5.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug Class (Neuraminidase Inhibitors, Others), Type (Branded, Generic), Patient Demographic (Adults, Geriatric, Pediatric), Indication (Influenza A, Influenza B, Others), Dosage Form (Capsule, Suspension), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), NATCO Pharma Limited (India), Macleods Pharmaceuticals Ltd (India), Strides Pharma Science Limited (India), Alembic Pharmaceuticals Limited (India), Hetero (India), Alvogen (U.S.), Sun Pharmaceutical Industries Ltd. (India), Zydus Cadila (India), Lotus International (U.S.)

Market Opportunities

  • Increase in the number of research and development activities
  • Rise in the development of advanced technologies

Market Definition

Tamiflu is an antiviral medicine that can be used to treat influenza. Tamiflu is an antiviral drug that works by suppressing the neuraminidase enzyme in the body, which aids in viral reproduction. This medicine stops new viruses from infecting host cells and activates enzymes (neuraminidases) found inside live organisms' cell membranes responsible for releasing offspring viruses after an infection with any organism. Furthermore, regular tamiflu treatment minimizes the severity of flu-related complications such as nausea, vomiting, and diarrhoea, lowering the risk of hospitalization due to viral fever or other influenza-related symptoms.

Tamiflu (Oseltamivir Phosphate) Drugs Market Dynamics

Drivers

  • Rise in the prevalence of influenza diseases

The surging prevalence of influenza diseases is a major factor driving the tamiflu (oseltamivir phosphate) drugs market's growth rate during the forecast period of 2022-2029. According to the Centers for Disease Control and Prevention (CDC), the flu affects between 5% and 20% of the population in the United States each year. In addition, 200,000 individuals are hospitalized in the United States each year due to flu infection, with 36,000 of them dying from flu complications. Tamiflu is used to treat acute and uncomplicated influenza A and B in patients aged 2 weeks and older who have been symptomatic for less than 48 hours. It is also prescribed for the prevention of influenza A and B in patients aged one year and up.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of tamiflu (oseltamivir phosphate) drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Following COVID-19, people's attitudes around health have shifted significantly. People's attitudes are evolving from disease treatment to disease prevention, and their total awareness of such drugs is increasing day by day. Governments around the world are investing more funding to improve and develop new healthcare infrastructure. Healthcare spending in the United States is expected to surpass 20% of GDP by 2028. All of these factors are estimated to drive the tamiflu (oseltamivir phosphate) drugs market forward.

Furthermore, rising initiatives by public and private organizations to spread awareness and rising healthcare expenditure will expand the tamiflu (oseltamivir phosphate) drugs market. Additionally, sedentary lifestyle of people and surging geriatric population will result in the expansion of tamiflu (oseltamivir phosphate) drugs market.

Opportunities

  • Increase in the number of research and development activities         

The rising research and development activities are estimated to create new opportunities for the tamiflu (oseltamivir phosphate) drugs market growth in coming years.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the tamiflu (oseltamivir phosphate) drugs market growth during the forecast period.

Restraints/Challenges

  • Side effects associated with tamiflu (oseltamivir phosphate) drugs

Side effects associated with tamiflu (oseltamivir phosphate) drugs will obstruct the growth rate of market. Severe side effects from oseltamivir include nausea, gastroenteritis, and stomach discomfort. It can lead to life-threatening health consequences in some situations, including heart attack, severe liver disease, and kidney problems. These limitations have the potential to stifle overall market growth.

On the other hand, the lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the tamiflu (oseltamivir phosphate) drugs market. Additionally, strict government regulations and the high cost of tamiflu (oseltamivir phosphate) drugs will restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This tamiflu (oseltamivir phosphate) drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tamiflu (oseltamivir phosphate) drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Tamiflu (oseltamivir phosphate) drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Tamiflu (Oseltamivir Phosphate) Drugs Market

The COVID-19 outbreak and subsequent lockdown in numerous countries around the world had a huge impact on the financial status of enterprises in all sectors. The private healthcare sector is one of the areas where the pandemic had a significant impact.

The outbreak of the COVID-19 virus has boosted the market for tamiflu (oseltamivir phosphate) drugs. A global pandemic has resulted from the rapid spread of the severe acute respiratory sickness COVID-19 in the human immunology population. COVID-19 particles may survive for several days on surfaces, although being enveloped viruses, they are susceptible to desiccation and mild detergent disinfection. Because nasal secretions contain the spreadable virus, disease progression and contagiousness appear to peak before or immediately after symptom onset. COVID-19 oral medication might be easily manufactured, transported, and stored, making it more convenient to obtain and use. Antivirals, such Tamiflu, are best taken as soon as possible to reduce the risk of serious illness. Tamiflu's strategy to treat COVID-19 has several advantages over current medications that require intravenous infusions, including monoclonal antibodies and convalescent plasma.

Global Tamiflu (Oseltamivir Phosphate) Drugs Market Scope

The tamiflu (oseltamivir phosphate) drugs market is segmented on the basis of indication, dosage form, drug class, type, patient demographic, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

  • Neuraminidase Inhibitors
  • Others

Type

  • Branded
  • Generic

Patient Demographic

  • Adults
  • Geriatric
  • Pediatric

Dosage Form

  • Capsule
  • Suspension

Indication

  • Influenza A
  • Influenza B
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Tamiflu (Oseltamivir Phosphate) Drugs Market Regional Analysis/Insights

The tamiflu (oseltamivir phosphate) drugs market is analysed and market size insights and trends are provided by country, indication, dosage form, drug class, type, patient demographic, route of administration, end-users and distribution channel as referenced above.

The countries covered in the tamiflu (oseltamivir phosphate) drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the tamiflu (oseltamivir phosphate) drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period,due to the presence of major key players and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, an increase in the number of FDA-approved drugs and high prevalence of influenzas illness will further propel the market’s growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to surging level of disposable income in this region. Also, development of healthcare infrastructure and rise in number of generic manufacturers will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Tamiflu (Oseltamivir Phosphate) Drugs Market Share Analysis

The tamiflu (oseltamivir phosphate) drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tamiflu (oseltamivir phosphate) drugs market.

Some of the major players operating in the tamiflu (oseltamivir phosphate) drugs market are:

  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Zydus Cadila (India)
  • Lupin (India)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Cipla Inc. (U.S.)
  • NATCO Pharma Limited (India)
  • Macleods Pharmaceuticals Ltd (India)
  • Strides Pharma Science Limited (India)
  • Alembic Pharmaceuticals Limited (India)
  • Hetero (India)
  • Alvogen (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Zydus Cadila (India)
  • Lotus International (U.S.)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Tamiflu (Oseltamivir Phosphate) Drugs Market size will be worth USD 862.85 billion by 2029.
The Tamiflu (Oseltamivir Phosphate) Drugs Market growth rate is 5.40% by 2029.
Rise in the prevalence of influenza diseases and Increasing investment for healthcare infrastructure are the growth drivers of the Tamiflu (Oseltamivir Phosphate) Drugs Market.
The indication, dosage form, drug class, type, patient demographic, route of administration, end-users and distribution channel are the factors on which the Tamiflu (Oseltamivir Phosphate) Drugs Market research is based.
The major companies in the Tamiflu (Oseltamivir Phosphate) Drugs Market are Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Lupin (India), Amneal Pharmaceuticals LLC. (U.S.), Cipla Inc. (U.S.), NATCO Pharma Limited (India), Macleods Pharmaceuticals Ltd (India), Strides Pharma Science Limited (India), Alembic Pharmaceuticals Limited (India), Hetero (India), Alvogen (U.S.), Sun Pharmaceutical Industries Ltd. (India), Zydus Cadila (India), Lotus International (U.S.).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials